

Transfers of Value to Health Professionals, Other Relevant Decision Makers and Healthcare Organisations

In accordance with the Association of the British Pharmaceutical Industry (ABPI) 2019 Code of Practice Alliance Pharmaceuticals Limited has publicly disclosed certain transfers of value made directly or indirectly to health professionals (HCPs), other relevant decision makers (ORDMs) and healthcare organisations (HCOs) in the UK.

These transfers of value include:

- Joint working.
- Donations, grants and benefits in kind provided to institutions, organisations and associations.
- Contracts between companies and institutions, organisations and associations.
- Sponsorship of attendance by health professionals and other relevant decision makers at meetings.
- Fees and expenses paid to health professionals and other relevant decision makers, or to their employers on their behalf.
- Contributions towards the costs of meetings paid to healthcare organisations or to third parties managing events on their behalf, which may include sponsorship of health professionals by way of registration fees and accommodation and travel.

For the purposes of this disclosure, Alliance Pharmaceuticals Limited has defined a donation and grant as transfer of value to an institution, organisation or association comprised of health professionals and/or that provide healthcare or conduct research. Sponsorship is defined as a meeting organised by a third party where costs to the healthcare professionals have been paid for (in full or in part) by Alliance, including registration fees, accommodation costs or travel. All fees and expenses have been disclosed separately.

Consent from the healthcare professional and healthcare organisation to disclose these transfers of value have been obtained on an individual activity basis through signed consultancy agreements or other written communication. Where recipients of transfers of value cannot be identified for legal reasons, the amount attributable to such transfers have been disclosed on an aggregate basis. The number of recipients involved have been stated together with the percentage of all recipients that they represent and the aggregate amount attributable to transfers of value to such recipients.

Only transfers of value relating to prescription medicines have been included within this disclosure, and any transfers of value relating solely to over the counter medicines, medical devices, cosmetics or food supplements have not been included in this disclosure.

Where an activity involves transfers of value relating to both prescription medicines and to these other categories of products, only the Alliance budgetary allocation relating to the prescription medicine is included in this disclosure. Where there was no split in budgetary allocation, the total of the transfer of value has been split equally by the number of brands that were promoted at that activity. In these instances, the split of budgetary allocation for such activities is available on request.

Disclosed payments relate to transfers of value where the payment transaction was completed in 2020. Any transfers of value relating to activity that spans two calendar years are disclosed in the year the transfer of value is completed.

All transfers of value are disclosed in Great British Pounds (£). Where a payment was fulfilled in another currency the value was converted into Great British Pounds based on the exchange rate at the time of payment. VAT has been included in the disclosed payments.

No non-monetary transfers of value were made by Alliance Pharmaceuticals Limited in 2020.

No transfers of value relating to collaborative working with other pharmaceutical companies and healthcare organisations were made by Alliance Pharmaceuticals Limited in 2020.